SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology reported its first commercial revenue of $2.1 million…

Kura Oncology, Inc. · 8-K filed Mar 5, 2026 at 06:36 ET

At the news

MIXEDIMPACT 6/10

8-K filed Mar 5, 2026 at 06:36 ET

Kura Oncology reported its first commercial revenue of $2.1 million from KOMZIFTI, its newly approved AML drug, in Q4 2025. Despite this milestone, the company reported a significant net loss increase to $81 million due to higher R&D and commercialization expenses. The company maintains a strong cash position of $667.2 million and anticipates $180 million in collaboration payments.

  • Generated $2.1 million in net product revenue from KOMZIFTI in Q4 2025 (first five weeks of sales)
  • Net loss increased to $81 million in Q4 2025 from $19.2 million in Q4 2024
  • Cash position of $667.2 million as of December 31, 2025
  • Anticipates $180 million in collaboration payments from Kyowa Kirin

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access